Good examples include the use of mTor inhibitors in renal cell carcinomas, epidermal growth factor receptor (EGFR) and PDL1 inhibitors in non-small cell lung carcinoma and the experimental use of insulin growth factor-1 receptor (IGF1R) inhibitors in sarcomas [26]. The gene discussed is EGFR; the disease is sarcoma.